Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Valacyclovir therapy does not reverse herpes-associated alterations in cervical immunology: a randomized, placebo-controlled crossover trial.

Yi TJ, Shannon B, Chieza L, Su D, Saunders M, Tharao W, Huibner S, Remis R, Raboud J, Kaul R.

J Infect Dis. 2014 Sep 1;210(5):708-12. doi: 10.1093/infdis/jiu163. Epub 2014 Mar 23.

2.

A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.

Yi TJ, Walmsley S, Szadkowski L, Raboud J, Rajwans N, Shannon B, Kumar S, Kain KC, Kaul R, Tan DH.

Clin Infect Dis. 2013 Nov;57(9):1331-8. doi: 10.1093/cid/cit539. Epub 2013 Aug 14.

3.

The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2.

Van Wagoner N, Geisler WM, Bachmann LH, Hook EW.

Int J STD AIDS. 2015 Jul;26(8):574-81. doi: 10.1177/0956462414546504. Epub 2014 Aug 21.

PMID:
25147236
4.

An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.

Fife KH, Warren TJ, Justus SE, Heitman CK; HS2100275 STUDY TEAM.

Sex Transm Dis. 2008 Jul;35(7):668-73. doi: 10.1097/OLQ.0b013e31816d1f42.

PMID:
18461016
5.

Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.

Roxby AC, Drake AL, Ongecha-Owuor F, Kiarie JN, Richardson B, Matemo DN, Overbaugh J, Emery S, John-Stewart GC, Wald A, Farquhar C.

PLoS One. 2012;7(6):e38622. doi: 10.1371/journal.pone.0038622. Epub 2012 Jun 12.

6.
7.

Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.

Nagot N, Ouédraogo A, Foulongne V, Konaté I, Weiss HA, Vergne L, Defer MC, Djagbaré D, Sanon A, Andonaba JB, Becquart P, Segondy M, Vallo R, Sawadogo A, Van de Perre P, Mayaud P; ANRS 1285 Study Group.

N Engl J Med. 2007 Feb 22;356(8):790-9.

8.

Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract.

Gupta R, Wald A, Krantz E, Selke S, Warren T, Vargas-Cortes M, Miller G, Corey L.

J Infect Dis. 2004 Oct 15;190(8):1374-81. Epub 2004 Sep 20.

9.

Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.

Zuckerman RA, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, Zuñiga R, Magaret AS, Wald A, Corey L, Celum C.

J Infect Dis. 2007 Nov 15;196(10):1500-8. Epub 2007 Oct 31.

10.

Impact of asymptomatic herpes simplex virus type 2 infection on mucosal homing and immune cell subsets in the blood and female genital tract.

Shannon B, Yi TJ, Thomas-Pavanel J, Chieza L, Janakiram P, Saunders M, Tharao W, Huibner S, Remis R, Rebbapragada A, Kaul R.

J Immunol. 2014 Jun 1;192(11):5074-82. doi: 10.4049/jimmunol.1302916. Epub 2014 Apr 23.

11.
12.

High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.

Perti T, Saracino M, Baeten JM, Johnston C, Diem K, Ocbamichael N, Huang ML, Selke S, Magaret A, Corey L, Wald A.

J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):201-8. doi: 10.1097/QAI.0b013e3182928eea.

13.

High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.

Mugwanya K, Baeten JM, Mugo NR, Irungu E, Ngure K, Celum C.

J Infect Dis. 2011 Dec 15;204(12):1912-7. doi: 10.1093/infdis/jir649. Epub 2011 Oct 12.

14.

Suppressive therapy with valacyclovir in early genital herpes: a pilot study of clinical efficacy and herpes-related quality of life.

Handsfield HH, Warren T, Werner M, Phillips JA.

Sex Transm Dis. 2007 Jun;34(6):339-43.

PMID:
17065847
16.

Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial.

Ouedraogo A, Nagot N, Vergne L, Konate I, Weiss HA, Defer MC, Foulongne V, Sanon A, Andonaba JB, Segondy M, Mayaud P, Van de Perre P.

AIDS. 2006 Nov 28;20(18):2305-13.

PMID:
17117016
17.

Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects.

DeJesus E, Wald A, Warren T, Schacker TW, Trottier S, Shahmanesh M, Hill JL, Brennan CA; Valacyclovir International HSV Study Group.

J Infect Dis. 2003 Oct 1;188(7):1009-16. Epub 2003 Sep 10. Erratum in: J Infect Dis. 2003 Nov 1;188(9):1404.

18.

HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men.

Zuckerman RA, Lucchetti A, Whittington WL, Sánchez J, Coombs RW, Magaret A, Wald A, Corey L, Celum C.

AIDS. 2009 Feb 20;23(4):479-83. doi: 10.1097/QAD.0b013e328326ca62.

19.

Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, Douglas JM Jr, Paavonen J, Morrow RA, Beutner KR, Stratchounsky LS, Mertz G, Keene ON, Watson HA, Tait D, Vargas-Cortes M; Valacyclovir HSV Transmission Study Group.

N Engl J Med. 2004 Jan 1;350(1):11-20.

20.
Items per page

Supplemental Content

Write to the Help Desk